MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.
In the company’s news,
Seeking Alpha yesterday published the following article featuring CytRx: http://seekingalpha.com/article/1700372-cytrx-corporation-remains-an-undiscovered-opportunity-inthe-cancer-space?source=yahoo#comments_header
Released On: 4/8/2016
Views: 3867
Released On: 4/7/2016
Views: 4617
Released On: 3/31/2016
Views: 3605
Released On: 3/24/2016
Views: 2940
Released On: 3/17/2016
Views: 2497
Released On: 3/11/2016
Views: 2341
Released On: 3/4/2016
Views: 2641
Released On: 3/3/2016
Views: 2331
Released On: 2/23/2016
Views: 3690
Released On: 2/12/2016
Views: 2691
Released On: 2/10/2016
Views: 2409
Released On: 2/9/2016
Views: 2562
Released On: 1/20/2016
Views: 4348
Released On: 1/14/2016
Views: 4811
Released On: 1/5/2016
Views: 3037
Released On: 12/18/2015
Views: 9373
Released On: 12/9/2015
Views: 2810
Released On: 12/3/2015
Views: 3255